IL6R and non-Hodgkin lymphoma: In particular, when stratifying primary Sjögren’s disease patients based on neoplastic evolution during the follow-up, IL-6R expression was significantly higher in patients who developed NHL (fold change: 21.20 ± 9.62) compared to both primary Sjögren’s disease patients who did not experience NHL transformation (fold change: 3.72 ± 0.80; p = 0.02) and the sicca disease cohort (fold change: 1.81 ± 0.44; p = 0.004) (Figure 3C).